| ¿µ¹® | multiple myeloma | ÇÑ±Û | ´Ù¹ß°ñ¼öÁ¾ |
|---|---|---|---|
| ¼³¸í | ´Ù¹ß¼º ¿ø¹ß¼º°ñÁ¾¾ç. ¸Ó¸®»À-°¥ºñ»À-º¹Àå»À-ôÃß»À-°ñ¹Ý µî¿¡ Àß ³ªÅ¸³ª°í, ¹°··¹°··ÇÑ Á¾±«¸¦ Çü¼ºÇϸç, »ÀÀÇ Èí¼ö°¡ ÀϾ°í, 40~60¼¼ ³²ÀÚ¿¡°Ô ¸¹ÀÌ ¹ß»ýÇÑ´Ù. °ñ¼öÁ¾ Á¾¾ç¼¼Æ÷´Â ÇüÁú¼¼Æ÷¿¡¼ À¯·¡ÇÑ °ÍÀÌ¾î¼ ÇüÁú¼¼Æ÷Á¾À̶ó°íµµ ÇÑ´Ù. °ú°Å¿¡´Â ÇüÁú¼¼Æ÷¼º°ñ¼öÁ¾ À̿ܿ¡´Â ´Ù¸¥ °ñ¼öÁ¶Ç÷¿ä¼Ò¿¡¼ »ý±â´Â °ñ¼öÁ¾À̶ó°í »ý°¢ÇßÁö¸¸ ÇöÀç´Â ºÎÁ¤µÇ°í ÀÖ´Ù. ÇüÁú¼¼Æ÷´Â ¿ø·¡ ¸é¿ª±Û·ÎºÒ¸°À» »ý»êÇÏ´Â ¼¼Æ÷À̸ç, ±×°ÍÀÌ Á¾¾çÈÇÑ ´Ù¹ß °ñ¼öÁ¾ ȯÀÚ¿¡¼µµ ´ëºÎºÐ Ç÷û ¼Ó¿¡ ¸é¿ª ±Û·ÎºÒ¸°ÀÌ Áõ°¡µÈ °ÍÀ» º¼ ¼ö ÀÖ´Ù. Áõ°¡ÇÑ ±Û·ÎºÒ¸°Àº IgG³ª IgAÀÎ °æ¿ì°¡ ¸¹Áö¸¸ ´Ù¸¥ Çüµµ ÀÖ´Ù. °ñ¼öÁ¾ ȯÀÚ ¾à 50%´Â ¿ÀÁÜ¿¡¼ º¥½ºÁÔ½º´Ü¹éÁúÀÌ °ËÃâµÇ´Âµ¥, ÀÌ ´Ü¹éÁúÀÇ ÃàÀû¿¡ ÀÇÇØ ¿ä¼¼°üÀÌ ÆÄ±«µÇ°í, ÄáÆÏ°æÈ°¡ ÀϾÙ. °ñ¼öÁ¾ ȯÀÚ¿¡¼´Â Ç÷û´Ü¹é ÀÌ»óÀ¸·Î °¡²û ¾Æ¹Ð·ÎÀ̵åÁõÀÌ ³ªÅ¸³´Ù. »À X¼± ¼Ò°ßÀ¸·Î¼´Â µµ·Á³½ º´ÅÍ, °ñÀ¶ÇØ»ó, º´Àû°ñÀýÀÌ °üÂûµÈ´Ù. |
||
| ¿µ¹® | protein | ÇÑ±Û | ´Ü¹éÁú |
|---|---|---|---|
| ¼³¸í | ź¼Ò, ¼ö¼Ò, »ê¼Ò, Áú¼Ò, ȲÀ» ÇÔÀ¯Çϰí ÀÖ´Â À¯±âÈÇÕ¹°·Î, ¸ðµç ¼¼Æ÷ÀÇ ¿øÇüÁúÀ» ÀÌ·ç°í ÀÖ´Â ±âº» ±¸¼º¹°ÁúÀÌ´Ù. ´Ü¹éÁúÀº ±× ´ÜÀ§ÀÎ ¾Æ¹Ì³ë»êµéÀÌ ÆéƼµå°áÇÕ¿¡ ÀÇÇØ °áÇյǾî ÀÖÀ¸¸ç, º¸Åë 20°³ÀÇ ¾Æ¹Ì³ë»êµéÀÌ ´Ù¸¥ ¼ø¼¿Í Á¶¼ºÀ» °¡Áö°í ¹è¿µÇ¾î, µ¶Æ¯ÇÑ ÇϳªÀÇ ´Ü¹éÁúÀ» Çü¼ºÇÏ°Ô µÈ´Ù. |
||
| B-J protein | Bence-Jones Protein ÀÇÀÇ; Multiple Myeloma |
|---|---|
| PC-BMP | phosphorylcholine-m-binding myeloma protein |
| MM | Multiple Myeloma |
| MM | macromolecule; Maelzels metronome; major medical [insurance]; malignant melanoma; manubrium to malle... |
| SMM | smoldering multiple myeloma |
| M.M. | Multiple Myeloma |
|---|---|
| MM | Myeloma |
| SMM | Smoldering multiple myeloma |
| HMCL | human myeloma cell line |
| G protein | 5'-triphosphate-binding protein |
| myeloma protein | <haematology, oncology> The immunoglobulins and Bence Jones proteins secreted by myeloma cells. (18 Nov 1997) |
|---|
| amyloidosis of multiple myeloma | Foci of amyloidosis in mesenchymal tissues of some persons with multiple myeloma; no direct relation between amyloid and Bence Jones protein is conclusively known. (05 Mar 2000) |
|---|---|
| cancer, multiple myeloma | A bone marrow cancer involving a type of white blood cell called a plasma (or myeloma) cell. The tumour cells can form a single collection (a plasmacytoma) or many tumours (multiple myeloma). Plasma cells are part of the immune system and make antibodies. Because patients have an excess of identical plasma cells, they have too much of one type of antibody. As myeloma cells increase in number, they damage and weaken the bones, causing pain and often fractures. When bones are damaged, calcium is released into the blood leading to hypercalcaemia (excess calcium in the blood) and that causes loss of appetite, nausea, thirst, fatigue, muscle weakness, restlessness, and confusion. Myeloma cells prevent the bone marrow from forming normal plasma cells and other white blood cells important to the immune system so patients may not be able to fight infections. The cancer cells can also prevent the growth of new red blood cells, causing anaemia. Excess antibody proteins and calcium may prevent the kidneys from filtering and cleaning the blood properly Cancer, non-Hodgkin's lymphoma: A lymphoma is a cancer that develops in the lymphatic system. The most common symptom of non-Hodgkin's lymphomas is a painless swelling in the lymph nodes in the neck, underarm, or groin. Non-Hodgkin's lymphomas are diagnosed with a biopsy of an enlarged lymph node. Follow-up examinations are important after lymphoma treatment. Most relapses occur in the first 2 years after therapy. (12 Dec 1998) |
| cancer, myeloma | A bone marrow cancer involving a type of white blood cell called a plasma (or myeloma) cell. The tumour cells can form a single collection (a plasmacytoma) or many tumours (multiple myeloma). Plasma cells are part of the immune system and make antibodies. Because patients have an excess of identical plasma cells, they have too much of one type of antibody. As myeloma cells increase in number, they damage and weaken the bones, causing pain and often fractures. When bones are damaged, calcium is released into the blood leading to hypercalcaemia (too much calcium in the blood) and that causes loss of appetite, nausea, thirst, fatigue, muscle weakness, restlessness, and confusion. Myeloma cells prevent the bone marrow from forming normal plasma cells and other white blood cells important to the immune system so patients may not be able to fight infections. The cancer cells can also prevent the growth of new red blood cells, causing anaemia. Excess antibody proteins and calcium may prevent the kidneys from filtering and cleaning the blood properly. (12 Dec 1998) |
| giant cell myeloma | A bone tumour composed of cellular spindle-cell stroma containing scattered multinucleated giant cells resembling osteoclasts. The tumours range from benign to frankly malignant lesions. The tumour occurs most frequently in an end of a long tubular bone in young adults. (12 Dec 1998) |
| plasma cell myeloma | Cells resemble mature or immature plasma cells with nuclei that appear cleaved or resemble immunoblasts. The tumour cells are CD19- , CD20- , CD22- and SIg- , but are also cIg+ and CD38+. The Ig heavy and light chain genes can be translocated or deleted. These neoplasms are often disseminated BM tumours of adults and progress to multiple myeloma. (05 Mar 2000) |
| multiple myeloma | <oncology, tumour> See myeloma cell. (18 Nov 1997) |
| myeloma | <oncology, tumour> A malignant tumour composed of plasma cells of the type normally found in the bone marrow. (18 Nov 1997) |
| myeloma cell | <haematology, oncology> Neoplastic plasma cell. The proliferating plasma cells often replace all the others within the marrow, leading to immune deficiency and frequently there is destruction of the bone cortex. Because they are monoclonal in origin they secrete a monoclonal immunoglobulin. Bence Jones proteins are monoclonal immunoglobulin light chains overproduced by myeloma cells and excreted in the urine. Myeloma cell lines are used for producing hybridomas in raising monoclonal antibodies. (18 Nov 1997) |
| endothelial myeloma | A malignant primary bone tumour that arises most commonly in the first three decades of life. It is highly malignant (prone to spread) and often requires treatment with some combination of radiation therapy and chemotherapy. (27 Sep 1997) |
| L-chain myeloma | bence Jones myeloma |
| acetoacetyl-acyl carrier protein synthase | <enzyme> E coli enzyme, that catalyses condensation of malonyl-acyl carrier protein plus acetyl-acyl carrier protein; not inhibited by cerulenin Registry number: EC 2.3.1.- Synonym: acetoacetyl-acp synthase (26 Jun 1999) |
| acid soluble spore protein | <molecular biology> A DNA binding protein in the spores of some bacteria, thought to stabilise the DNA in an A configuration, so protecting it from cleavage by enzymes or UV light. (18 Nov 1997) |
| acute-phase protein | <haematology> These plasma proteins (in addition to fibrinogen) increase 25% or more in response to inflammation and injury are under direct control of interleukin-6 (IL-6) (hepatocyte-stimulating factor). Other proteins which increase are ceruloplasmin, C3 and C4 which increase 50% or more; alpha-1 acid glycoprotein, alpha-1 antitrypsin, haptoglobin and fibrinogen (the major determinant of viscosity 1 ) which increase two- to fourfold; C-reactive protein (CRP) and serum amyloid A which increase several hundred-fold. Despite long-held clinical opinion to the contrary, available data indicate that neither ESR nor measurement of specific acute-phase reactants are useful in excluding underlying infection or inflammation regardless of the pretest probability. These proteins are secreted into the blood in increased or decreased quantities by hepatocytes in response to trauma, inflammation, or disease. They can serve as inhibitors or mediators of the inflammatory processes. Certain acute-phase proteins have been used to diagnose and follow the course of diseases or as tumour markers. See also: amyloid, c-reactive protein, erythrocyte sedimentation rate, viscosity. (25 Jun 1999) |
| acyl-(acyl-carrier-protein)-phospholipid acyltransferase | <enzyme> Catalyses the formation of phosphatidylethanolamine from acyl-acyl carrier protein and 2-acyl-sn-glycero-3-phosphoethanolamine Registry number: EC 2.3.1.40 Synonym: 2-acyl-gpe acyltransferase, 2-acylglycerophosphoethanolamine acyltransferase (26 Jun 1999) |
| acyl-(acyl-carrier-protein)-UDP-N-acetylglucosamine acyltransferase | <enzyme> E coli enzyme involved in lipid a biosynthesis; uses beta-hydroxymyristoyl-acyl carrier protein to form udp-3-monoacyl-n-acetylglucosamine; amino acid sequence given in second source Registry number: EC 2.3.1.129 Synonym: udp-aguatransferase, lpxa protein, udp-n-acetylglucosamine-3-acyltransferase, udp-n-acetylglucosamine 3-o-acyltransferase, udp-3-o-(r-3-hydroxymyristoyl)glucosamine-n-acyltransferase, lpxd protein, fira gene product, fira protein (26 Jun 1999) |
Synonyms : M Components, Proteins, Myeloma
| myeloma protein |
any of the pathological immunoglobulin proteins or fragments, such as M component and Bence-Jones protein, secreted by myeloma cells.
Ãâó: www.mercksource.com/pp/us/cns/cns_hl_dorlands.jspz...
|
|---|
Á¦Ç°¸í |
ÆÇ¸Å»ç |
º¸ÇèÄÚµå | ¼ººÐ/ÇÔ·® | ±¸ºÐ/º¸Çè±Þ¿© |
|---|
Á¦Ç°¸í |
ÆÇ¸Å»ç |
º¸ÇèÄÚµå | ¼ººÐ/ÇÔ·® | ±¸ºÐ/º¸Çè±Þ¿© |
|---|